Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials
UMass Chan Affiliations
Department of NeurologyDocument Type
Journal ArticlePublication Date
2007-04-11Keywords
Acute DiseaseAnimals
Clinical Trials as Topic
Endpoint Determination
Humans
Neuroprotective Agents
Reperfusion Injury
Research Design
Stroke
Neurology
Metadata
Show full item recordAbstract
The concept of neuroprotective therapy for acute ischemic stroke to salvage tissue at risk and improve functional outcome is based on sound scientific principles and extensive preclinical animal studies demonstrating efficacy. The failure of most neuroprotective drugs in clinical trials has been due to inadequate preclinical testing and flawed clinical development programs. The Stroke Therapy Academic Industry Roundtable (STAIR) group has outlined rational approaches to preclinical and clinical studies. The positive results from the first Stroke-Acute-Ischaemic-NXY-Treatment (SAINT-I) trial of the free-radical spin-trap drug, NXY-059, which followed many of the STAIR guidelines, reinvigorated enthusiasm in neuroprotection, but the SAINT-II trial did not replicate the positive effect on the same primary prespecified outcome measure. This has led to concerns about the future of neuroprotection as a therapeutic strategy for acute ischemic stroke. We discuss new suggestions to bridge the chasm between preclinical animal modeling and acute human stroke trials to potentially enhance the future assessment of novel neuroprotective drugs.Source
Ann Neurol. 2007 May;61(5):396-402. Link to article on publisher's siteDOI
10.1002/ana.21127Permanent Link to this Item
http://hdl.handle.net/20.500.14038/37638PubMed ID
17420989Related Resources
Link to article in PubMedae974a485f413a2113503eed53cd6c53
10.1002/ana.21127